Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 14/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 13/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 13/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13813625 | 0.95 | ITGAL (0.31) | ITGALITGB2ICAM1 | |
| SCHEMBL3385514 | 0.83 | ITGAL (0.33) | ITGALITGB2ICAM1 | |
| SCHEMBL14025846 | 0.81 | ITGAL (0.37) | ITGALITGB2ICAM1 | |
| SCHEMBL14025847 | 0.73 | ITGAL (0.31) | ITGALITGB2ICAM1 | |
| SCHEMBL4638373 | 0.69 | ITGAL (0.36) | ITGALITGB2ICAM1 | |
| SCHEMBL4638112 | 0.69 | ITGAL (0.36) | ITGALITGB2ICAM1 | |
| SCHEMBL4849625 | 0.69 | ITGAL (0.38) | ITGALITGB2ICAM1 | |
| SCHEMBL4797185 | 0.69 | ITGAL (0.38) | ITGALITGB2ICAM1 | |
| SCHEMBL4849619 | 0.69 | ITGAL (0.38) | ITGALITGB2ICAM1 | |
| SCHEMBL4917004 | 0.67 | CCR5 (0.36) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | NOVARTIS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| EP-2209371-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE BIOSCIENCE INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160220702-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE BIOSCIENCE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-20080242710-A1 | Pharmaceutically Active Tetrahydro-Pyrrolo[1,2-B]Isothiazole 1,1-Dioxides | BAUMANN KARL | 2008-10-02 | — | — | US | disclosed |
| US-20080242710-A1 | Pharmaceutically Active Tetrahydro-Pyrrolo[1,2-B]Isothiazole 1,1-Dioxides | BAUMANN KARL | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB2 11/4885ICAM1 3/4885 |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB2 11/4885ICAM1 3/4885 |
| US-20080242710-A1 | Pharmaceutically Active Tetrahydro-Pyrrolo[1,2-B]Isothiazole 1,1-Dioxides | ICAM1, VCAM1, SELPLG | ITGAL 18/4885ITGB2 10/4885ICAM1 1/4885 |
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB2 11/4885ICAM1 3/4885 |
| US-20160220702-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB2 11/4885ICAM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.